Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual…
A simpler blood test for cancer recurrence risk works as well as tumor-specific tests, potentially opening faster treatment decisions for triple-negative breast cancer patients.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma
Transplantation offers half of patients with this rare aggressive lymphoma a chance at long-term survival, with donor stem cells outperforming patient's own cells.
Novel or significantly improved treatmentSPEN inactivation drives resistance to androgen receptor pathway…
A newly discovered resistance mechanism to prostate cancer drugs appears in one in thirty patients after treatment, helping doctors anticipate when therapy might stop working.
Novel or significantly improved treatmentDual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in…
Blocking two immune checkpoints instead of one produces more complete tumor responses in this ultra-rare soft tissue sarcoma than single-drug approaches historically achieved.
Near-term implementable findingReal-World Experience With TRBC1 Immunohistochemistry Across…
A staining technique rivals molecular genetic testing for diagnosing skin T-cell lymphomas while costing less and being easier to implement in routine practice.